| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/28/2004 | EP1384719A1 Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections |
| 01/28/2004 | EP1384710A1 Synthesis of heterocyclic compounds containing five- or six-membered rings |
| 01/28/2004 | EP1384485A1 Bactericidal/permeability increasing protein or biologically active analogs thereof to treat lipopolysaccharide associated gram negative infections |
| 01/28/2004 | EP1384482A1 External skin compositions |
| 01/28/2004 | EP1384481A1 Remedies for vesical hyperesthesia |
| 01/28/2004 | EP1384480A1 Remedies for vesical hyperactivity |
| 01/28/2004 | EP1384479A1 Preventing or reducing photosensitivity and/or phototoxicity reactions to antiinfective medications |
| 01/28/2004 | EP1384478A1 Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose |
| 01/28/2004 | EP1384477A1 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases |
| 01/28/2004 | EP1384476A1 Azolylcarbynol derivatives of aryl (or heteroaryl) for the treatment of respiratory diseases |
| 01/28/2004 | EP1384475A1 Liver funcion protecting or ameliorating agent |
| 01/28/2004 | EP1384474A1 Injectable composition containing taxol |
| 01/28/2004 | EP1384473A1 Stable gabapentin containing more than 20 ppm of chlorine ion |
| 01/28/2004 | EP1384472A1 Method for producing an organic solvent-free lycopene concentrate, the resulting concentrate and composition comprising said concentrate |
| 01/28/2004 | EP1384471A1 Osmotic extented-release dosage form |
| 01/28/2004 | EP1384081A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
| 01/28/2004 | EP1383931A1 Nucleic acid vaccines for prevention of flavivirus infection |
| 01/28/2004 | EP1383922A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 01/28/2004 | EP1383919A1 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/28/2004 | EP1383895A2 Polynucleotides and polypeptides of the ifnalpha-5 gene |
| 01/28/2004 | EP1383884A2 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| 01/28/2004 | EP1383883A2 Asthma-associated snps around microsatellite marker d2s308 and identification of human prolyl-oligopeptidase-dpp10 |
| 01/28/2004 | EP1383799A1 Probes, systems and methods for drug discovery |
| 01/28/2004 | EP1383787A2 Sapogenin derivatives, their synthesis and use |
| 01/28/2004 | EP1383786A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| 01/28/2004 | EP1383782A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| 01/28/2004 | EP1383778A2 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 01/28/2004 | EP1383774A2 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/28/2004 | EP1383772A2 Nitrogen-based camptothecin derivatives |
| 01/28/2004 | EP1383769A2 6-substituted pyrazolo 3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| 01/28/2004 | EP1383768A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 01/28/2004 | EP1383767A1 Trifluoromethylpurines as phosphodiesterase 4 inhibitors |
| 01/28/2004 | EP1383766A1 Disubstituted 1,7-guanines |
| 01/28/2004 | EP1383765A1 Chemical compounds |
| 01/28/2004 | EP1383762A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same |
| 01/28/2004 | EP1383761A1 Phenyl- and pyridyl-piperidines with tnf activity |
| 01/28/2004 | EP1383760A1 Biarylcarboxamide compounds as apolipoprotein b inhibitors |
| 01/28/2004 | EP1383759A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| 01/28/2004 | EP1383757A1 Antagonists of mcp-1 function and methods of use thereof |
| 01/28/2004 | EP1383756A1 Coumarin derivatives to be used as anticoagulants |
| 01/28/2004 | EP1383753A1 Piperazine-benzamide derivatives useful as apob-100 and/or mtp inhibitor |
| 01/28/2004 | EP1383752A2 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds |
| 01/28/2004 | EP1383751A1 Novel azoles having an insecticidal action |
| 01/28/2004 | EP1383750A2 Urea derivatives as integrin alpha 4 antagonists |
| 01/28/2004 | EP1383749A1 Arylsulfonamides as antiviral agents |
| 01/28/2004 | EP1383748A2 Novel compounds and compositions as cathepsin inhibitors |
| 01/28/2004 | EP1383747A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| 01/28/2004 | EP1383746A2 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds |
| 01/28/2004 | EP1383744A1 Novel piperidine derivatives as modulators of chemokine receptor |
| 01/28/2004 | EP1383743A2 Dual inhibitors of pde 7 and pde 4 |
| 01/28/2004 | EP1383741A2 Process for the preparation of benazepril |
| 01/28/2004 | EP1383740A2 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
| 01/28/2004 | EP1383739A1 New compounds |
| 01/28/2004 | EP1383736A2 Peptide deformylase inhibitors |
| 01/28/2004 | EP1383735A1 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof |
| 01/28/2004 | EP1383734A2 Compounds useful as intermediates for 4-aminoquinoline derivatives |
| 01/28/2004 | EP1383733A2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds |
| 01/28/2004 | EP1383731A1 Biaryl compounds as serine protease inhibitors |
| 01/28/2004 | EP1383730A2 Anticholinergic compounds and methods of use |
| 01/28/2004 | EP1383729A1 Peptide deformylase inhibitors |
| 01/28/2004 | EP1383579A2 Composition, containing carnitine and huperzin for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder |
| 01/28/2004 | EP1383578A1 Single dose aromatase inhibitor for treating infertility |
| 01/28/2004 | EP1383573A2 Methods and apparatus for treating diseased tissue |
| 01/28/2004 | EP1383556A1 Injection device for administering rna |
| 01/28/2004 | EP1383539A1 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 01/28/2004 | EP1383527A1 Methods and compositions for treating oral and esophageal lesions |
| 01/28/2004 | EP1383523A2 Agent for treating diabetes mellitus |
| 01/28/2004 | EP1383518A1 Oral delivery of macromolecules |
| 01/28/2004 | EP1383517A1 Use of cationic dextran derivatives for protecting dose-limiting organs |
| 01/28/2004 | EP1383516A1 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 01/28/2004 | EP1383515A1 Activation of natural killer cells by adenosine a3 receptor agonists |
| 01/28/2004 | EP1383514A1 Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters |
| 01/28/2004 | EP1383512A1 Use of sucralfate for the treatment of cervical erosion |
| 01/28/2004 | EP1383511A2 Calcilytic compounds |
| 01/28/2004 | EP1383510A1 Bisphosphonate conjugates and methods of making and using the same |
| 01/28/2004 | EP1383509A1 A drug for use in bone grafting |
| 01/28/2004 | EP1383508A1 Methods of treating acne |
| 01/28/2004 | EP1383507A1 Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances |
| 01/28/2004 | EP1383506A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7 |
| 01/28/2004 | EP1383505A2 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease |
| 01/28/2004 | EP1383504A1 Sustained release drug delivery system containing codrugs |
| 01/28/2004 | EP1383503A2 Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops |
| 01/28/2004 | EP1383502A2 Compounds and methods for the treatment of urogenital disorders |
| 01/28/2004 | EP1383501A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 01/28/2004 | EP1383500A1 Composition and method for the treatment of respiratory disease |
| 01/28/2004 | EP1383499A2 Method of immunomodulation using thione-forming disulfides |
| 01/28/2004 | EP1383498A1 Crf receptor antagonists |
| 01/28/2004 | EP1383497A2 Carbonic anhydrase activators for enhancing learning and memory |
| 01/28/2004 | EP1383496A2 Treatment of fibromyalgia and related fatigue syndromes using pindolol |
| 01/28/2004 | EP1383495A1 Duloxetine for treatment of hot flashes |
| 01/28/2004 | EP1383494A2 Compositions and methods for the prevention and treatment of human prostate cancer |
| 01/28/2004 | EP1383493A1 Inhibition of pigmentation by inhibition of fatty acid synthase |
| 01/28/2004 | EP1383492A1 Molecular conjugates for use in treatment of cancer |
| 01/28/2004 | EP1383491A2 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
| 01/28/2004 | EP1383490A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 01/28/2004 | EP1383489A1 Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| 01/28/2004 | EP1383487A1 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
| 01/28/2004 | EP1383486A2 Compositions containing cgmp pde inhibitors and local anestetic agents for nasal application |
| 01/28/2004 | EP1383483A1 Controlled delivery of tetracycline compounds and tetracycline derivatives |
| 01/28/2004 | EP1383482A2 Method for manufacturing a low dose pharmaceutical composition |